Plain-English translation of NCT05231629 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The MASTER-2 trial is testing whether doctors can personalize treatment for newly diagnosed multiple myeloma by measuring how well the cancer responds to initial therapy with daratumumab. Patients who achieve the best response may avoid a stem cell transplant, while those who don't respond as well will be offered additional treatment options, including a transplant combined with newer medications.
Current treatment for multiple myeloma often includes a stem cell transplant, which is intensive and carries risks. This trial is trying to figure out whether some patients can skip the transplant if their cancer responds very well to this medication, while identifying which patients would benefit most from receiving a transplant plus newer drugs.
You likely qualify if…
You likely don't qualify if…
All participants start with 6 cycles of combination drug treatment to measure how well their cancer responds. Depending on your response, you may either receive 3 more cycles of treatment followed by ongoing maintenance therapy, or proceed to a stem cell transplant (if needed) followed by different maintenance medications. The study involves regular clinic visits for treatment, blood tests, and bone marrow assessments to track your cancer response over approximately 2 years.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States